Evidence map›Paper›PMID 29974364›Full record

ArticleMolecular diversity2019

Synthesis and biological evaluation of novel SIPI-7623 derivatives as farnesoid X receptor (FXR) antagonists.

Si-Yun Nian, Guo-Ping Wang, Zheng-Li Jiang, Ying Xiao, Mo-Han Huang, Yi-Huan Zhou, Xiang-Duan Tan

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Si-Yun NianDepartment of Clinical Pharmacy, Taizhou Hospital of Zhejiang Province, Xi Men Street No. 150, Linhai, 317000, Zhejiang Province, China.
Guo-Ping WangShanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, 201203, China.
Zheng-Li JiangDepartment of Clinical Pharmacy, Taizhou Hospital of Zhejiang Province, Xi Men Street No. 150, Linhai, 317000, Zhejiang Province, China.
Ying XiaoShanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, 201203, China.
Mo-Han HuangCollege of Pharmacy, Guilin Medical University, Guilin, 541004, China.
Yi-Huan ZhouCollege of Pharmacy, Guilin Medical University, Guilin, 541004, China.
Xiang-Duan TanCollege of Pharmacy, Guilin Medical University, Guilin, 541004, China. tandy@glmc.edu.cn.

Funding

Guangxi Natural Science Foundation of China No.2015GXNSFBA139124National Natural Science Foundation of China No. 81660571
6 · The paper itself

Abstract

Most of reported steroidal FXR antagonists are restricted due to low potency. We described the design and synthesis of novel nonsteroidal scaffold SIPI-7623 derivatives as FXR antagonists. The most potent compound A-11 (IC

Indexed as

HumansMolecular Docking SimulationReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearValeratesReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearValeratesFXR antagonistsGuggulsteroneMolecular dockingSIPI-7623Structure activity relationship

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.